Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020
Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities……………
Total Pages: 75
Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth. Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. Introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness. Further key findings from the study suggest: Long acting insulin was the leading product segment in 2013 and is expected to grow at the CAGR of over 15.0% during the forecast period. The introduction of advanced products, high prices associated with these products and the phasing out of human insulin are some key factors attributing for its large share. North America was the most matured antidiabetics market in 2013 accounting for over 43.0% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth. Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers. Some key market players of antidiabetics include Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer. For the purpose of this study, Grand View Research has segmented the global antidiabetics market on the basis of product and region: Global Insulin Product Outlook (Revenue, USD Million, 2012 – 2020) Global Antidiabetics Product Outlook (Revenue, USD Million, 2012 – 2020) Antidiabetics Regional Outlook (Revenue, USD Million, 2012 – 2020) Table of Contents Chapter 1. Executive Summary 1.1. Antidiabetics– Industry Summary and Critical Success Factors (CSFs) Chapter 2. Antidiabetics Industry Outlook 2.1. Market Segmentation 2.2. Market size and growth prospects 2.3. Antidiabetics – Market dynamics 2.3.1. Market driver analysis 2.3.1.1 Growing prevalence of diabetes 2.3.1.2 Presence of a strong product pipeline portfolio 2.3.1.3 Growing prevalence of lifestyle induced disorders such as obesity 2.3.2. Market Restraint Analysis 2.3.2.1. High insulin prices 2.4. Key Opportunities Prioritized 2.5. Industry Analysis – Porter’s 2.6. Antidiabetics – PESTEL analysis 2.7. Antidiabetics market – Pipeline overview Chapter 3. Antidiabetics Product Outlook 3.1. Antidiabetics market share by product, 2013 & 2020 3.2. Insulin 3.2.1. Insulin market share, by product, 2013 & 2020 3.2.2. Rapid acting analog market 3.2.2.1. Rapid acting analog market, 2012 – 2020 (USD Million) 3.2.3. Long acting analog market 3.2.3.1 Long acting analog market, 2012 – 2020 (USD Million) 3.2.4. Premixed analog market 3.2.4.1 Premixed analog market, 2012 – 2020 (USD Million) 3.2.5. Premixed insulin market 3.2.5.1. Premixed insulin market, 2012 – 2020 (USD Million) 3.2.6. Short acting insulin market 3.2.6.1. Short acting insulin market, 2012 – 2020 (USD Million) 3.2.7. Intermediate acting insulin market 3.2.7.1 Intermediate acting insulin market, 2012 – 2020 (USD Million) 3.3. Other antidiabetics 3.4. Alpha glucosidase inhibitors 3.4.1. Alpha glucosidase inhibitors market, 2012 – 2020 (USD Million) 3.5. Biguanides 3.5.1. Biguanides market, 2012 – 2020 (USD Million) 3.6. Sulphonylureas 3.6.1. Sulphonylureas market, 2012 – 2020 (USD Million) 3.7. GLP 1 (Glucagon like peptide) agonists 3.7.1. GLP 1 agonist market, 2012 – 2020 (USD Million) 3.8. DPP - 4 (Dipeptyl peptides) inhibitors 3.8.1. DPP-4 market, 2012 – 2020 (USD Million) 3.9. Meglitinides 3.9.1. Meglitinides market, 2012 – 2020 (USD Million) 3.10. SGLT - 2 (sodium glucose transport proteins) inhibitors 3.10.1. SGLT - 2 inhibitors market, 2012 – 2020 (USD Million) 3.11. Thiazolodinediones 3.11.1. Thiazolodinediones market, 2012 – 2020 (USD Million) Chapter 4. Antidiabetics Regional Outlook 4.1. Antidiabetics market share, by region, 2013 & 2020 4.2. North America antidiabetics market 4.2.1. North America antidiabetics market, 2012 – 2020 (USD Million) 4.3. Europe antidiabetics market 4.3.1. Europe antidiabetics market, 2012 – 2020 (USD Million) 4.4. Asia Pacific antidiabetics market 4.4.1. Asia Pacific antidiabetics Market, 2012 – 2020 (USD Million) 4.5. RoW antidiabetics market 4.5.1. RoW antidiabetics market, 2012 – 2020 (USD Million) Chapter 5. Competitive Landscape 5.1 Sanofi Aventis 5.1.1 Company Overview 5.1.2 Financial Performance 5.1.3 Product Benchmarking 5.1.4 Strategic Initiatives 5.2 Takeda Pharmaceuticals 5.2.1 Company Overview 5.2.2 Financial Performance 5.2.3 Product Benchmarking 5.2.4 Strategic Initiatives 5.3 Eli Lilly 5.3.1 Company Overview 5.3.2 Financial Performance 5.3.3 Product Benchmarking 5.3.4 Strategic Initiatives 5.4 Oramed Pharmaceuticals Inc. 5.4.1 Company Overview 5.4.2 Financial Performance 5.4.3 Product Benchmarking 5.4.4 Strategic Initiatives 5.5 Merck & Co. Inc. 5.5.1 Company Overview 5.5.2 Financial Performance 5.5.3 Product Benchmarking 5.5.4 Strategic Initiatives 5.6 Novo Nordisk 5.6.1 Company Overview 5.6.2 Financial Performance 5.6.3 Product Benchmarking 5.6.4 Strategic Initiatives 5.7 Bristol-Myers Squibb 5.7.1 Company Overview 5.7.2 Financial Performance 5.7.3 Product Benchmarking 5.7.4 Strategic Initiatives 5.8 Halozyme Therapeutics 5.8.1 Company Overview 5.8.2 Financial Performance 5.8.3 Product Benchmarking 5.8.4 Strategic Initiatives 5.9 Pfizer 5.9.1 Company Overview 5.9.2 Financial Performance 5.9.3 Product Benchmarking 5.9.4 Strategic Initiatives Chapter 6. Methodology and Scope 6.1. Research Methodology 6.2. Research Scope & Assumptions 6.3. List of Data Sources List of Tables 1. Antidiabetics – Industry Summary & Critical Success Factors (CSFs) List of Figures 1. Antidiabetics market segmentation |